Thus, an increase in WNT5A gene transcription in patients of the PoCR group compared to the HD group can be explained by the fact that after therapy, more active metabolic processes occurred in damaged HD, both associated with the restoration of bone tissue and with the expression of signaling molecules and receptors by the MM cells themselves. This evidence concerns the gene WNT5A and Huntington disease.